Neutralisation of systemic anticoagulation with heparin in cardiac surgery with cardiopulmonary bypass requires protamine administration. If adequately dosed, protamine neutralises heparin and reduces the risk of postoperative bleeding. However, as its anticoagulant properties are particularly exerted in the absence of heparin, overdosing of protamine may contribute to bleeding and increased transfusion requirements. This narrative review describes the mechanisms underlying the anticoagulant properties and side-effects of protamine, and the impact of protamine dosing on the activated clotting time and point-of-care viscoelastic test results, and explains the distinct protamine dosing strategies in relation to haemostatic activation and postoperative bleeding. The available evidence suggests that protamine dosing should not exceed a protamine-to-heparin ratio of 1:1. In particular, protamine-to-heparin dosing ratios >1 are associated with more postoperative 12 h blood loss. The optimal protamine-to-heparin ratio in cardiac surgery has, however, not yet been elaborated, and may vary between 0.6 and 1.0 based on the initial heparin dose.
the beginning of the 20th century. 3e6 Moreover, it was shown that adding increasing quantities of protamine sulphate to fresh whole blood prolonged the clotting time, 7 which was appointed to interference with the conversion from prothrombin to thrombin. 8, 9 From these studies, it became apparent that the dosing of protamine is crucial in the shift towards an anticoagulant effect. 7 The number of publications focusing on protamine dosing is relatively small compared with studies on heparin dosing (Fig. 1) , and evidence levels for protamine dosing strategies in available guidelines are low. 10, 11 Protamine use and dosing are controversial, and are frequently based on local practices and individual experience rather than evidence, with a large range of protamine-to-heparin ratios reported in the literature. Moreover, it is still common to administer additional protamine in continuing oozing patients, whilst the origin of coagulopathy and microvascular bleeding is not related to residual heparin. The ignorance of the anticoagulant properties of excessive protamine may result in prolonged bleeding and increased transfusion requirements. The objective of this review was to present an overview of the anticoagulant properties and sideeffects of protamine; the evidence for the unfavourable effects of protamine overdosing on patient haemostasis; and recent studies focusing on optimising protamine dosing using heparin monitoring, fixed protamine-to-heparin dosing strategies, or algorithm-based protamine dosing.
Mechanism of action
Protamine is a highly positively charged peptide consisting of about 32 amino acids, and neutralises the effect of heparin through electrostatic binding between the cationic arginine groups of protamine and the anionic heparin in a 1:1 ratio. The resulting neutral protamineeheparin salt aggregates are clearly visible as white suspension and are formed within seconds. 12 In parallel, the binding of protamine to heparin dissociates the anti-thrombin/heparin complex, leading to the recovery of the original anti-thrombin activity. 13e16 The neutralisation of heparin by protamine is further influenced by platelet factor 4 (PF4), a heparin-binding protein excreted by activated platelets. PF4 is complimentary to protamine regarding heparin neutralisation, and during extracorporeal circulation, PF4 release contributes to the stability of the protamineeheparin complex. 17 Protamine has a rapid onset of action, a heparin-neutralising effect within 5 min for unfractioned heparin, and a relatively short half-life of about 10 min in healthy volunteers in the absence of heparin administration as determined by highperformance liquid chromatography. 18 In patients undergoing cardiac surgery with cardiopulmonary bypass (CPB), 250 mg of protamine sulphate administered as infusion over 5 min in the presence of heparin showed a median plasma clearance of protamine of 1.4 litres min À1 (0.61e3.8) and a median half-life of 4.5 min (1.9e18), as estimated by a two-compartment exponential model with a volume distribution of 0.066 litres kg
À1
. 19 Clearance of low-molecular-weight heparin by protamine depends on the molecular weight of heparin, with small heparin fragments being more difficult to neutralise than larger molecules. 20 There is only little insight in the metabolism of the neutral protamineeheparin salt complex. One animal study using radiolabelled heparin showed that heparineprotamine complexes are mainly metabolised in the liver, 21 whilst infusion of radiolabelled protamine in the absence of heparin in a rat study showed that it is mainly metabolised and excreted by the kidneys.
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Anticoagulant properties of protamine
Whilst protamine primarily neutralises heparin, protamine has anticoagulant properties that are attributed to an interaction with platelet function, interference with coagulation factors, and stimulation of clot breakdown. The effects of protamine on different functions in the haemostasis system are summarised in Figure 2 .
Effect of protamine on platelet count, activation, and aggregation
Exposure to protamine may result in thrombocytopenia, 23 reduced thrombin-induced platelet aggregation, 24 and decreased platelet responsiveness to thrombin receptor agonist peptide. 25 Using a protamine-dose range from 0 to 60 mg ml À1 , Shigeta and colleagues 26 showed in a small patient study that the inhibitory effects of protamine on platelet aggregation are dose dependent and can be minimised by adaptation of the protamine dose to the residual heparin concentration at the end of CPB. Moreover, high doses of protamine (200 mg ml
À1
) reduced the glycoprotein Ib interaction with surface-bound von Willebrand factor (vWF) in platelet-rich plasma, and decreased the plateletecollagen adhesion under shear stress in an in vitro set up.
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Protamine reduced the platelet aggregation by 50% in heparinised patients undergoing cardiac surgery with CPB. 23 This study was, however, limited by a 1:1 protamine-to-heparin dosing ratio that was calculated for the initial heparin dose administered during CPB regardless of heparin consumption, and additional protamine dosing was allowed. 28 Similar findings were reported in patients undergoing pulmonary thromboendarterectomy with deep cooling receiving protamine-toheparin ratios exceeding 1. 29 An in vitro study also showed that blood spiked with a protamine-to-heparin dosing ratio ranging from 1:1 to 10:1 reduces adenosine diphosphate (ADP)-induced platelet aggregation in a protamine-dose-dependent fashion.
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In summary, protamine reduces platelet activity and aggregation, but the underlying mechanism is multifactorial. Reduced thrombin generation, inhibition of glycoprotein IbevWF activity, and the release of intracellularly stored ADP and PF4 31 may all account for the platelet modulating effects of protamine.
Interference with coagulation factors
In vitro experiments previously elaborated that protamine mediates the down-regulation of thrombin generation, leading to a reduced conversion of fibrinogen to fibrin, 32,33 reduces the rate of factor V activation by thrombin and factor Xa, 34 and decreases factor VII activation by tissue factor thrombin activity. 35 In haemophilia patients, a direct drop in factor VII clotting activity was observed upon protamine-dose ranges between 30 and 100 mg ml À1 , irrespective of the presence of heparin.
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In a study of patients receiving a high (1.3:1) or low (0.8:1) protamine-to-heparin ratio, the recovery of thrombin generation after heparin neutralisation was impaired in the highprotamine-dosing group. 37 In particular, the high protamineto-heparin dosing ratio was associated with an increased lag time, reduced endogenous thrombin potential, and reduced peak thrombin concentrations compared with the low dosing ratio. 37 The inhibitory effects of protamine on thrombin generation can be neutralised by the addition of platelets or increased factor VIII/vWF concentrations. 38, 39 The aforementioned observations could also be confirmed during functional viscoelastic testing, showing that incremental doses of protamine or protamine-to-heparin dosing ratios exceeding 1:1 resulted in a prolonged clotting time of the intrinsic coagulation test. 37, 38, 40, 41 Rotational thromboelastometry experiments further show that the administration of extra protamine in cardiosurgical patients with an abnormal activated clotting time (ACT) after CPB results in a brief prolongation of clotting times. 42 In agreement with these findings, it was shown that in vitro administration of protamine in a 3:1 dosing ratio to heparinised patient blood prolongs the thromboelastographic clot initiation time six-fold compared with a 1:1 dosing ratio, and impairs clot kinetics and platelet function. 43 From these observations, it can be concluded that protamine may interfere with coagulation factors involved in clot formation, especially in the case of higher protamine doses.
Stimulation of clot breakdown
The decreased thrombin concentrations associated with protamine administration may also potentiate fibrinolysis.
44,45
In vitro experiments in human plasma showed that protamine reduces clot strength and the time to clot lysis, and enhances tissue-type plasminogen-activator-mediated fibrinolysis, thereby promoting clot breakdown. 44 These observations could be counteracted by the addition of tissue factor to the plasma samples. 44 Although protamine-related hyperfibrinolysis might be of relevance in cardiac surgery with CPB, the routine use of anti-fibrinolytic therapy in clinical practice may prevent this phenomenon.
Side-effects of protamine
Protamine administration is associated with immunological and inflammatory alterations, and may induce an anaphylactic response with hypotension, bradycardia, pulmonary vasoconstriction, and allergy, as the most frequently reported side-effects. 46 55 In vitro studies further showed a link between protamine-related antibodies and thrombocytopenia. 55, 56 However, despite the development of protamineeheparin antibodies, an association with unfavourable clinical outcome has not been demonstrated.
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Patients with an allergy to fish protein are at risk to develop an anaphylactic response to protamine with IgE antibody formation as common pathway. Subcutaneous testing of a small dose of protamine may be indicated in patients with severe allergy to fish protein, and bivalirudin may be used as an alternative anticoagulation agent in this population. 57 
Complement activation
Exposure to CPB activates the complement system through the alternative pathway, whilst protamine administration is associated with complement activation through the classic C4a pathway.
58e61 Incubation of patient plasma with heparin and protamine demonstrated that protamine-induced complement activation is stimulated by the C-reactive protein. 59 Patients who developed complement C-reactive protein complexes more frequently developed postoperative arrhythmia. 58, 59 Moreover, the cumulative activation of both complement pathways by the extracorporeal circuit and protamine may contribute to a pro-inflammatory response after cardiac surgery.
Vasoplegia
Infusion of protamine is frequently associated with a transient drop in blood pressure and a rise in pulmonary arterial pressure. 62 Vascular reactivity to protamine is most likely mediated by increased mechanical stretch-induced intracellular endothelial calcium release, as shown in isolated human umbilical vein endothelial cells, 63 and nitric oxide production, as shown in human internal thoracic artery rings. 64 Unwanted effects of protamine on perioperative blood pressure can be prevented by administration of an antihistaminic agent to suppress an allergic reaction and hydrocortisone to reduce the inflammatory response. 46 Alternatively, nitric-oxide-mediated vasoplegia after protamine infusion can be treated by methylene blue, which inhibits nitric oxide synthase and guanylate cyclase. 65 
Pulmonary hypertension
Pulmonary hypertension is the most severe clinical complication after a protamine-induced anaphylactic response.
Comunale and colleagues 66 reported a protamine-induced pulmonary hypertensive response defined as an increase in mean pulmonary arterial pressure of >7 mm Hg in 0.6% of patients. In a second report, 1.78% of patients developed pulmonary hypertension with right ventricular failure after protamine administration. 67 It is assumed that thromboxane release underlies the pathophysiological mechanism underlying this severe complication, 68e71 and can be treated by prostacyclin EI infusion. 67, 72 Others suggested that protamine-induced pulmonary hypertension can be prevented by continuation of acetylsalicylic acid intake before surgery. 66 Because of the low incidence of pulmonary hypertension after protamine infusion, clinical data on this topic are mainly restricted to case reports.
Rate and location of protamine infusion
The protamine-related haemodynamic side-effects are enlarged when protamine is rapidly infused over a 3 min period when compared with a 15 min infusion period. 73 Moreover, slow infusion of protamine over a 30 min period was associated with a favourable postoperative coagulation profile when compared with fast bolus administration. 16 Chaney and colleagues 74 investigated whether the location of protamine infusion influenced the adverse event rate. They showed that administration of protamine via the ascending aorta was the least associated with blood pressure and arterial oxygenation changes compared with administration through the central venous line, albeit that the changes were not clinically relevant and transient. 74 These observations suggest that the adverse effects of protamine administration may be diminished by choosing a slow infusion method and the correct location of infusion.
Point-of-care haemostatic testing for protamine effects
Point-of-care coagulation tests for perioperative anticoagulation monitoring in cardiac surgery are primarily used to detect heparin anticoagulation and residual heparin. However, because of the effects of protamine on the coagulation system, these tests may also be affected by protamine itself. Table 1 provides an overview of available haemostatic tests that are commonly used and that are sensitive to protamine effects. The celite or kaolin ACT is typically used to assess the heparin-neutralising effects of protamine after CPB. Theoretically, the ACT should return to preoperative values after protamine administration. Yet, there is substantial evidence that the post-protamine ACT does not accurately reflect the concentrations of residual heparin. In an in vitro study, it was shown that the ACT increases with incremental protamine-toheparin dosing ratios. 30 In particular, an escalation in the dosing ratio from 1.3 to 2.6 was associated with an increase in the ACT from 143 (13) to 162 (16) s. 30 It was further shown that a prolonged ACT after heparin neutralisation by 1:1 protamine administration has no predictive value in detecting residual heparin. 75 Others showed a weak correlation between the ACT (r¼0.26), 76 celite ACT (r¼0.34), 77 and kaolin ACT (r¼0.59) 77 with heparin concentrations or a non-linear relation between ACT and heparin values. 78 Additionally, several reports show that, despite the use of different protamine-to-heparin dosing ratios in comparative study arms, the post-protamine ACT values were comparable. (13) and 129 (16) s (P¼0.35), respectively. 79 These findings suggest that the ACT cannot be used to titrate protamine dosing. A combination of a heparin doseeresponse and heparineprotamine titration test enables the exact titration of heparin and protamine for an individual patient, and can be used as an alternative for the ACT. The worldwide introduction of viscoelastic testing for haemostasis monitoring in cardiac surgery allows the specific evaluation of residual heparin after CPB. However, the heparinase-containing INTEM rotational thromboelastometry test for intrinsic coagulation monitoring has also shown to be sensitive for protamine. Multiple observational clinical studies showed that the INTEM is prolonged in case of higher protamine-to-heparin dosing ratios.
40e42, 82 The reason for this effect of protamine is unrevealed, but the observation has now been included as a warning in the device manual by the manufacturer. In 82 patients undergoing coronary surgery or valve surgery who were randomised to ACT-or thromboelastography-based protamine dosing, it was shown that both ACT and thromboelastography strategies were associated with similar protamine-to-heparin dosing ratios and bleeding rates. 83 In summary, these data suggest that users of viscoelastic test devices should be aware of the testmodulating effects of both heparin and protamine, and that these tests should be interpreted accordingly.
Protamine dosing strategies
Ideally, protamine dosing should be guided by its effect on patient haemostasis or by measurement of heparin concentrations, taking heparin consumption during extracorporeal circulation into account. As the ACT does not reflect post-CPB heparin concentrations, additional protamine administration based on a prolonged post-CPB ACT compared with pre-CPB levels can be harmful instead of beneficial for patient haemostasis. In order to understand the impact of inadequate protamine dosing, a theoretical distinction should be made between the effects of protamine under-and overdosing (Fig. 3) . Current protamine dosing practices are, therefore, increasingly based on protamine-to-heparin dosing ratios, low anticoagulation strategies, model-based titration, or measurement-based titration. We here describe the available evidence for these different protamine dosing strategies.
Ratio-based dosing
Protamine-to-heparin dosing ratio strategies vary amongst institutions and are subjected to local conventions. The dosing ratio is either based on the initial heparin dose or the total heparin dose administered during surgery, where protamine dosing based on the initial heparin dose takes heparin consumption during bypass into account. The number of clinical studies focusing on the impact of different protamine-toheparin dosing ratios on postoperative bleeding and transfusion requirements is, however, limited ( Table 2) . Despotis and colleagues 84 used a protamine-to-heparin dosing ratio of 0.8 for the total heparin dose administered in 487 patients, with the possibility to infuse additional protamine in case of a post-CPB ACT that did not return to pre-CPB levels. In a multivariate analysis, they showed that a larger total protamine dose was independently associated with a higher risk of postoperative transfusions. 84 Others reported prolonged ACTs, 30 abnormal viscoelastic clotting times, 41 and impaired ADP-induced platelet aggregation 30 when the protamine-to-heparin dosing ratio was above 1.3. In a small prospective study, randomisation of patients to a 0.8 vs 2.0 protamine-to-heparin dosing ratio revealed that high protamine dosing was associated with changes in platelet count and PF4, whilst post-protamine ACT levels were similar amongst groups. 81 In a randomised controlled trial in coronary artery bypass graft (CABG) patients, we showed that a protamine-to-heparin dosing ratio of In contrast, one retrospective cohort study investigating three different protamine dosing regimens in 300 CABG patients suggested that a protamine-to-heparin dosing ratio of 1:3 was associated with lower packed-red-blood-cell transfusion rates (1% vs 7%) than a ratio of 0.75, respectively. 85 Finally, in low anticoagulation protocols in combination with a tip-to-tip biocompatible coated extracorporeal circuit aiming for a target ACT of 250e300 s, the total dose of protamine administered is reduced by about 50% because of the lower anticoagulation approach. 86e88 Except for the study by Meesters and colleagues, 37 none of the aforementioned studies were powered to detect a difference in postoperative blood loss or transfusion requirements.
Model-based titration of protamine
There is increasing interest in the application of mathematical or pharmacokinetic (PK) algorithms for heparin and protamine dosing to support the optimisation of perioperative systemic anticoagulation in cardiac surgery. In particular, the estimation of a post-CPB heparin concentration, which takes heparin consumption over time into account, may improve the accuracy of protamine dosing. Table 3 provides an overview of available algorithms for heparin and protamine dosing that are currently available. Delavenne and colleagues 89 showed that a PK/pharmacodynamic model can be used for monitoring of the anticoagulation effect and calculation of an adequate protamine dose after CPB using the inhibitory effects of heparin on FXa as validation method. 89 Jia and colleagues 90 developed a two-compartment PK model based on antithrombin (FIIa) concentrations to predict heparin concentrations during hypothermic cardiac surgery. In particular, the level of thrombin inhibition by the heparin/anti-thrombin complex was used as an index to estimate plasma heparin concentrations. 90 They suggested that their approach would result in a lower protamine-dose regime after termination of CPB. 90 Others developed a model based on perioperative kaolin ACT measurements to calculate the post-CPB protamine dose, which resulted in a 17.8% decrease in protamine dosing compared with a conventional group. 91 The model included baseline and post-heparin ACT values, patient weight, and the bolus of heparin administered to the patient, and was based on the individual heparin response of a patient and the assumption that protamine 1 mg neutralises heparin 1 mg. 92 However, the study was biased by the excessive volumes of chest tube drainage in both groups. 91 In a group of patients receiving heparin and protamine based on computer-based algorithm, the protamine-to-heparin dosing ratio was reduced from 0.81 to 0.49 with less postoperative bleeding in the algorithm group compared with the Table 2 Association of different protamine-to-heparin ratios and patient haemostasis. ACT, activated clotting time; CI, confidence interval; PF4, platelet factor 4; P:H, protamine-to-heparin dosing ratio; PRBC, packed red blood cell; RCT, randomised controlled trial. Data represent mean (standard deviation) or median ((inter-quartile) range) finally included body surface area, the administered dose of heparin, heparin clearance based on the total dose of administered heparin and the time elapsed between the first bolus of heparin and protamine administration, and the preoperative platelet count. The predicted required dose of protamine using the statistical model was in accordance with the advised protamine dose by the haemostasis management system as reference. 94 In a second study, the same investigators implemented this model in a randomised controlled fashion, and compared protamine dosing and postoperative coagulation with patients exposed to a protamine-to-heparin dosing ratio of 1:1. 95 Whilst the heparin dosing was similar in both groups, they showed a reduction in protamine dosage from 426 (43) to 251 (66) 
Protamine titration based on heparin measurements
Titration of protamine based on measured post-CPB heparin concentrations may improve the accuracy of heparin neutralisation and contribute to preserved patient haemostasis. Protamine titration is usually based on the measured heparin concentration, anti-FIIa, or anti-FXa concentrations. There are several publications available focusing on the effects of protamine titration on postoperative bleeding and transfusion in cardiac surgery, with conflicting results.
Study identification
The most frequent clinically applied method for protamine titration is based on the measurement of post-CPB heparin concentrations using a haemostasis management system (Hepcon/HMS ® ) Hemochron RxDx device or protamine-dose assay. Despite several attempts to develop novel protaminetitration assays, including ultracentrifugation or an automatic protein dose assay, these methods never gained widespread acceptance in routine clinical care. 97, 98 Both electronic and hand-searching techniques were used to identify studies from PubMed, Ovid EMBASE, and the Cochrane Central Register of Controlled Trials from January 1990 to January 2017. The following search terms were used: adult cardiac surgery, protamine, protamine titration, Hepcon/HMS, RxDx, and protamine-dose assay. The search yielded 486 studies, of which 185 studies were clinical trials. Decisions for inclusion were based on independent review of the abstracts by two study investigators (C.B. and M.I.M.). Studies were excluded in case of the following criteria: (i) no direct comparison of protamine titration with an ACT or fixed protamine-to-heparin ratio strategy, (ii) performed in paediatric surgery, and (iii) no original study or conference abstract. The protamine-to-heparin dosing ratios (P:H) are either based on the initial heparin dose 98, 102, 108, 112 or total heparin dose, and ratios reported in these studies vary from 0.33 26 to 1.3. 112 In half of the studies, a reduction in the protamine-to-heparin dosing ratio was associated with improved haemostatic test results 26,101,102,108 or less postoperative bleeding. 79, 103, 104, 111, 112 One group showed no difference in 12 h blood loss between the fixed protamine-dose and protamine-titration groups [median 495 (range 150e1460) vs median 475 (range 300e1070) ml, respectively; P¼0.81], but this can be explained by almost similar protamine-to-heparin dosing ratios in both groups [0.84 (0.14) vs 0.86 (0.19); P¼0.57]. 99 Others reported no difference in postoperative blood loss when an ACT and protaminetitration strategy were compared. 105e107, 110 Finally, two studies reported increased blood loss after protamine titration. The first study found increased 6 h blood loss in the protamine-titration group. 109 Albeit not the primary endpoint, the second study also reported higher 12 h blood loss volumes in the protamine-titration group {median 420 [inter-quartile range (IQR) 337.5e605.0] ml} compared with the control group [median 345 (IQR 230.0e482.5) ml; P¼0.0041]. 100 It is, however, unknown whether the mixed inclusion of on-pump, OPCAB, and miniaturised extracorporeal therapy cases, and the absent publication of concomitant ACT values may have influenced these results.
Results
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In summary, despite the availability of several protaminetitration studies, the quality of studies is limited and clinical outcomes, such as postoperative blood loss or blood transfusion, were only rarely used as primary study endpoints. Moreover, the wide range in publication years (1994e2015) may introduce a bias, as cardiosurgical strategies have been largely improved over the last decade. In particular, modern cardiosurgical practices frequently implement a multifactorial and multidisciplinary patient blood management programme to reduce transfusion rates. Larger randomised controlled trials in the modern cardiosurgical setting are warranted to understand the impact of protamine titration on clinical relevant outcomes, including postoperative blood loss and transfusion requirements.
In order to gain insight in the relationship between protamine-to-heparin dosing ratios and 12 h blood loss, an analysis was performed of studies comparing distinct protamine dosing strategies based on a fixed ratio, 37 model-based protamine titration, 95, 96 and protamine titration based on heparin measurements 79 ,99e101,104,105 that reported 12 h blood loss (Fig. 4) . For the purpose of this review, a scatterplot was made for the protamine-to-heparin ratio against the volume of 12 h blood loss, which showed a moderately good correlation (r¼0.52; 95% CI 0.07559e0.7961; P¼0.026). We here show that there might be a trend between protamine dosing and postoperative blood loss, albeit that these data have methodological limitations and are mostly retrieved from studies where postoperative bleeding or transfusion was not the primary endpoint, from mixed cardiosurgical populations with different perioperative strategies.
Additional protamine administration
When the post-protamine ACT exceeds the pre-CPB ACT, it is common in some hospitals to add additional protamine doses for neutralisation of residual heparin. However, in light of the weak correlation between post-protamine ACT levels and residual heparin, it is unclear whether these additional protamine doses act as a heparin-neutralising agent or an anticoagulant. Consequently, the administration of additional doses of protamine after compensating for the heparin dose may lead to protamine overdosing and enhanced bleeding. In 1968, Berger and colleagues 114 already showed that administration of protamine in smaller aliquots resulted in sufficient restoration of clot formation after the first dose when compared with a full protamine dose, resulting in a protamine-dose administration of 1.37 vs 0.79 mg for every 100 IU of heparin, respectively. Others found that the administration of additional protamine in an in vitro setting resulted in an increased clotting time expressed as the thromboelastometry R value, which ranged from 12.95 (range 5.2e37.8) min for a protamine-to-heparin ratio of 1:1 to 78.5 (range 6.3e822.0) min for a protamine-to-heparin dosing ratio of 3:1. 43 In a small randomised controlled study in bypass graft and valve surgery, 54% of the control patients received additional protamine doses, which was associated with more 24 h blood loss [1298 (747) ml] when compared with a heparin response test group, where only 32% of patients received additional protamine [671 (333) ml; P¼0.01)]. 115 Whether additional protamine dosing is beneficial for patient outcome should be further investigated in view of the inadequacy of post-protamine ACT levels to reflect the presence of residual heparin.
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Avoidance of heparin rebound
Heparin rebound is the recurrence of anticoagulant activity after heparin neutralisation with protamine caused by the release of heparin from protein-binding sites, and is frequently attributed to protamine underdosing. Heparin rebound is a feared phenomenon, as it might contribute to postoperative bleeding and increased transfusion requirements. The phenomenon is, however, complicated by the diversity in definitions of heparin rebound and the absent accuracy of most coagulation tests to detect heparin rebound. 116 In particular, in most studies, the definition of heparin rebound is only limited to the presence of heparin in blood, without investigating its effect on postoperative bleeding complications. It was recently shown that heparin rebound might be of less importance as cause for postoperative bleeding than previously assumed, showing no correlation between postprotamine heparin concentrations and the total volume of blood loss (r¼0.35; P¼0.106). 117 Others showed that different protamine-to-heparin dosing ratios ranging from 1.1 to 0.8 are associated with similar incidences of heparin rebound. 110 Additionally, we showed that post-protamineeheparin concentrations at 3 min after protamine administration were similar in high [1.04 (0.50) IU,ml À1 ] and low [1.21 (0.45) IU,ml À1 ; P¼0.246] protamine dosing ratio groups, and no heparin rebound in the late postoperative period was reported. 37 Others found that a low-dose protamine infusion (25 mg h À1 for 6 h) after heparin neutralisation prevented heparin rebound as defined by the thrombin clotting time and anti-FXa concentrations. 118 They further showed that a protamine infusion aborts the presence of heparin after surgery, which was associated with a non-relevant reduction in postoperative bleeding when compared with control patients.
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Alternatives for protamine A strategy to avoid the side-effects and dosing complications of protamine is the use of alternatives for unfractionated heparin or protamine. The direct thrombin inhibitor, bivalirudin, is the most commonly used replacement for heparin anticoagulation. Bivalirudin has no antidote and is eliminated with a half-life of approximately 25 min, thereby avoiding the use of protamine. 119 In a randomised controlled trial, Dyke and colleagues 120 showed that bivalirudin can be safely and effectively used for systemic anticoagulation during cardiac surgery, without differences in blood loss compared with heparin anticoagulation. However, as stasis should be avoided during bivalirudin, this anticoagulation therapy requires adjustments of perfusion approaches. Its use is, therefore, mainly restricted to patients with HIT antibodies where surgery cannot be postponed and the bleeding risk is acceptable. 121 Because of the sideeffects of protamine, several experimental alternatives have been suggested, 122 including PF4, 123 heparinase, 25,124 and hexadimethrine. 125 Although their heparin-neutralising capacities could be proved, widespread introduction in the clinical setting
has not yet been realised.
Discussion
The current recommendations for protamine dosing by the Task Force on Patient Blood Management for Adult Cardiac Surgery of the European Association for Cardio-Thoracic Surgery and the European Association of Cardiothoracic low levels of evidence. The recommendations suggest the use of protamine titration and the avoidance of protamine-toheparin dosing ratios exceeding 1. Here, we provided an overview of the available evidence for protamine dosing strategies, indicating that there is increasing interest in blood-heparinconcentration measurements and the application of heparinisation algorithms to implement tailored heparin and protamine management in cardiac surgery. In particular, the use of algorithms may contribute to individualisation of heparin and protamine dosing strategies and preserved haemostasis. Future studies should focus on the evaluation of the effectiveness and validation of these models before application of these algorithms can be extended to general clinical practice.
Conclusions
Protamine reversal of heparin anticoagulation is a necessary evil in cardiac surgery with or without CPB, and can be associated with haemostatic abnormalities when inadequately dosed. The available evidence suggests that protamine administration based on the initial heparin dose should target a ratio below 1:1 in order to prevent protamine-related coagulopathy and bleeding, but the exact ratio is not elaborated and may vary between 0.6 and 1.0 based on the initial heparin dose. Large randomised controlled trials comparing a protamine-to-heparin dosing ratio of 1.0 to 0.7 in order to test the hypothesis that a high protamine dosing ratio is associated with increased postoperative transfusion rates are warranted to improve the quality of evidence for this topic. 
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